Pipeline
We’re working to identify more unmet medical needs and focus our research where it is needed most. Our growing pipeline includes therapies aimed at providing new solutions in cancer care and rare diseases where no options currently exist, with a goal to help lift the burden of cancer for patients.
Cancer Therapeutics
Vepafestinib1
Solid Tumors with RET Abnormalities
Cancer Supportive Care
Fosnetupitant - Palonosetron
Pediatric CINV2
Fosnetupitant - Palonosetron IV
IV - China - CINV2,3
Anamorelin4
Global - Cancer Anorexia-Cachexia in NSCLC5 patients
Other
HM04
Ghrelin Receptor Antagonist - Prader-Willi Syndrome - Open for partnering
HM01
Ghrelin Receptor Agonist - Partnered
Notes
The safety and efficacy of the agents identified for the investigational uses have not been established: these agents have not been approved for commercial use by any regulatory authority worldwide, except where noted. There is no guarantee that they will receive health authority approval or become commercially available in any country for the uses being investigated.
1.Vepafestinib is co-developed by Helsinn Healthcare SA and Taiho Pharmaceutical Co. Ltd.
2.Chemotherapy-Induced Nausea and Vomiting
3.Approved in multiple territories, including USA and EU
4.Approved in Japan
5.Non-Small Cell Lung Cancer